Head-To-Head Analysis: BioNTech (NASDAQ:BNTX) vs. TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Volatility & Risk

TScan Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for TScan Therapeutics and BioNTech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1	5	2	0	2.12
BioNTech	1	5	12	1	2.68

TScan Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 684.31%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 27.89%. Given TScan Therapeutics’ higher possible upside, research analysts plainly believe TScan Therapeutics is more favorable than BioNTech.

Institutional and Insider Ownership

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 6.2% of TScan Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares TScan Therapeutics and BioNTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
BioNTech	-63.54%	-6.86%	-6.00%

Valuation & Earnings

This table compares TScan Therapeutics and BioNTech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32 million	2.23	-$129.77 million	($0.91)	-0.37
BioNTech	$3.25 billion	7.67	-$1.29 billion	($7.83)	-12.58

TScan Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

BioNTech beats TScan Therapeutics on 10 of the 15 factors compared between the two stocks.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.